Global Tangential Flow Filtration Market

Tangential Flow Filtration Market Size, Share, Growth Analysis, By Product(Single-use Tangential Flow Filtration Systems, Reusable Tangential Flow Filtration Systems), By Technology(Ultrafiltration, Microfiltration), By Application(Protein Purification, Vaccine and Viral Vectors), By End-use(Pharmaceutical & Biotechnology Companies, Contract Research Organizations & Contract Manufacturing Organizations) - Industry Forecast 2024-2031


Report ID: SQMIG35H2128 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 121 | Figures: 77

Tangential Flow Filtration Market Insights

Global Tangential Flow Filtration Market size was valued at USD 2.10 Billion in 2022 and is poised to grow from USD 2.34 Billion in 2023 to USD 5.61 Billion by 2031, at a CAGR of 11.53% during the forecast period (2024-2031).

Tangential flow filtration technology is growing in popularity to meet the increased demand for biopharmaceuticals for the management of different diseases and degenerative diseases including diabetes, cancer, & rheumatoid arthritis. This trend is the primary factor driving the market. Tangential flow filtration's (TFF) advantages, such as its high performance & reproducible operations, as well as companies increasing involvement in the creation of fresh TFF products, are also having an effect on the market's growth.

Additionally, ongoing industry expenditures and encouraging government initiatives have led to facility expansions and active R&D for the creation of new tools and technologies that are used in the production of biopharmaceuticals. The mass manufacture of the COVID-19 vaccine and the rising demand for biopharmaceuticals have opened up a slew of new options for major firms. Additionally, the utilization of single-use TFF equipment among end-users has increased due to the growing acceptance of single-use biological processing equipment for the production of biopharmaceuticals. To address the rising demand for single-use technology required for the production of the COVID-19 vaccine, for instance, Pall Corporation invested a total of USD 114 million.

The additional advantages of TFF above traditional flow filtration add to the high utilization rate and continue to drive the market growth. A few benefits of TFF systems include increased flow rate, reduced product build-up, removing filter aids, simplified cleaning, and filter replacement. Additionally, because TFF is a continuous filtering process, it takes less time to run and is now automated thanks to technology improvements. Automated filtering systems extend the process's resilience and productivity by decreasing fouling of the membrane, which eventually lengthens the membrane's shelf life. These advantages have led to the use of TFF systems in the production of biopharmaceuticals. Several firms have also improved their marketplace presence and created cutting-edge technology. For instance, Repligen Corporation received a patent in 2021 for their Tangential Flow Depth Filtering (TFDF) filter, which offers a one-use solution with little hold-up volume and lots of flux. Over the forecast period, such advancements and breakthroughs in this field are anticipated to fuel industry expansion.

US Tangential Flow Filtration Market is poised to grow at sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Tangential Flow Filtration Market size was valued at USD 2.10 Billion in 2022 and is poised to grow from USD 2.34 Billion in 2023 to USD 5.61 Billion by 2031, at a CAGR of 11.53% during the forecast period (2024-2031).

As a result of its advantages and swift adoption by bio-manufacturers, the industry has been expanding without end for the past few years. Key companies in the TFF market now have worthwhile chances thanks to the rising application in domains like immunology, microbiology, and protein purification procedures. A large product line of filtering products for a variety of applications has also led to considerable income generating. Players use a variety of strategic efforts, including alliances, acquisitions, new product launches, and collaborations, to achieve a competitive advantage. 'Merck KGaA', 'Sartorius AG', 'GE Healthcare', 'Thermo Fisher Scientific Inc.', 'Danaher Corporation', 'MilliporeSigma', 'Repligen Corporation', '3M Company', 'Pall Corporation (a division of Danaher Corporation)', 'Parker Hannifin Corporation', 'Asahi Kasei Corporation', 'Alfa Laval AB', 'Eppendorf AG', 'Spectrum Laboratories, Inc. (a subsidiary of Repligen Corporation)', 'Cole-Parmer Instrument Company LLC', 'GEA Group AG', 'Novasep Holding S.A.S.', 'Filtration Group Corporation', 'Starlab Scientific Co., Ltd.', 'Alfa Wassermann Separation Technologies S.p.A.'

The growing demand for biopharmaceutical products, such as monoclonal antibodies, vaccines, and recombinant proteins, is a significant driver for the TFF market. TFF is widely used in the biopharmaceutical industry for the purification and concentration of these products.

Increasing Adoption of Single-use TFF Systems: The market is witnessing a growing trend towards the use of single-use TFF systems. Single-use TFF offers several advantages, including reduced cross-contamination risk, simplified cleaning and validation processes, and increased operational flexibility. The convenience and cost-effectiveness of single-use systems are driving their adoption across various biopharmaceutical manufacturing processes.

North America had the highest revenue share (almost 40.0%) in 2022. Regional growth has been aided by the expansion of bioprocessing facilities to fulfill the demand for biotherapeutics, the rise in the prevalence of chronic diseases & genetic conditions, growing public knowledge of the safety of medical interventions, and the development of healthcare environments. In addition, having a helpful government promotes development. For instance, the budget for 2021 from the Government of Canada included around USD 0.7 billion (CAD 1 billion) in funding for the growth of life sciences and biomanufacturing companies. This financing is provided for a period of more than seven years through the Strategic Innovation Fund. In order to increase domestic demand for medicines and vaccines in Canada, Biovectra, a CDMO, upgraded its Nova Scotia biologics facility & constructed a new facility in Prince Edward Island.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Tangential Flow Filtration Market

Product ID: SQMIG35H2128

$5,300
BUY NOW GET FREE SAMPLE